Combined treatment with two cancer immunotherapy drugs - one a novel immune modulator and one that focuses and activates the antitumor immune response - significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.
Original Article: Combined treatment prolongs survival in mouse models of malignant mesothelioma